Novo Nordisk | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
ANI Pharmaceuticals USD 69.72M 9.36M 2024-12
Aurora Cannabis CAD 38.18M 2.05M 2024-12
Bausch Health Companies USD 850M 18M 2024-09
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Canopy Growth CAD 40.62M 308K 2024-12
Corcept Therapeutics USD 83.37M 9.63M 2024-12
Drreddys Laboratories INR 21.59B 436M 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
GlaxoSmithKline GBP 2.66B 1.14B 2024-12
Merck USD 2.85B 148M 2024-12
Novartis USD 3.5B 368M 2024-12
Novo Nordisk 16.59B 501M 2024-09
Novo Nordisk DKK 16.59B 501M 2024-09
Pacira USD 79.61M 5.28M 2024-12
Perrigo USD 234.8M 36.7M 2024-12
Prestige Brands USD 64.13M 3.35M 2024-12
Sanofi EUR 2.68B 26M 2024-09
Supernus Pharmaceuticals USD 79.41M 9.66M 2024-12
Zoetis USD 625M 60M 2024-12



Novo Nordisk Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.